8-K

0001193125-21-056938.txt : 20210225 0001193125-21-056938.hdr.sgml : 20210225 20210225160607 ACCESSION NUMBER: 0001193125-21-056938 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210225 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210225 DATE AS OF CHANGE: 20210225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 21680251 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 8-K 1 d138712d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2021

Translate Bio, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-38550	61-1807780
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

29 Hartwell Avenue Lexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 945-7361

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of exchange

on which registered

Common Stock, $0.001 par value

TBIO

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On February 25, 2021, Translate Bio, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


Exhibit		Description of Document

99.1		Press Release dated February 25, 2021

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	TRANSLATE BIO, INC.

Date: February 25, 2021	By:	/s/ Paul Burgess
		Paul Burgess
		Chief Operating Officer, Chief Legal Officer and Secretary

EX-99.1 2 d138712dex991.htm EX-99.1 EX-99.1

EXHIBIT 99.1

LOGO

Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress

— Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) —

— Two infectious disease mRNA vaccine programs expected to enter clinic in 2021: COVID-19 in Q1 and influenza in mid-2021, in collaboration with partner Sanofi Pasteur —

— Established TBIO 2025 long-term strategic plan to leverage established mRNA platform and measured growth to capture mRNA opportunities in multiple therapeutic areas —

LEXINGTON, Mass. – February 25, 2021 – Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2020.

“2020 ushered in a new era of mRNA possibilities—for vaccines and therapeutics—in which the promise of mRNA medicines became a reality,” said Ronald Renaud, chief executive officer of Translate Bio. “We are optimistic and remain focused on our mission of developing mRNA medicines to treat or prevent diseases and we look forward to several anticipated milestones in 2021, including the next interim analysis from our clinical trial in patients with CF early in the second quarter, and the planned initiation of two clinical programs by our partner, Sanofi Pasteur: a COVID-19 vaccine candidate in the first quarter and an influenza vaccine candidate in mid-2021.”

Renaud continued, “With a deep mRNA scientific foundation, a strong cash position and positive momentum across our pipeline, we believe we are well-positioned to capture the significant potential of mRNA. We have established TBIO 2025, a strategic plan that emphasizes several areas for value creation with a focus on advancing multiple investigational new drug applications (INDs), new pipeline programs and platform innovation over the next five years. This plan will be aimed at enhancing speed, flexibility and control across our research engine so that we continue to be at the forefront of the discovery and development of transformative mRNA medicines.”

2020 and Recent Accomplishments

•

MRT5005 for the Treatment of CF, Phase 1/2 Clinical Trial: Completed dosing in cohorts for the second interim data analysis, which is expected to be reported in early Q2 2021. These include multiple-ascending dose (MAD) groups (8, 12 and 16 mg), and a single-ascending dose (SAD) group (20 mg).

•

Other Pulmonary Programs: Advanced next-generation CF and primary ciliary dyskinesia (PCD) programs with positive preclinical data generated to support planned initiation of IND-enabling studies in the second half of 2021.

•

Infectious Disease Vaccine Programs: Executed two expansions of the collaboration with Sanofi Pasteur, for COVID-19 in March 2020 and for all infectious disease vaccines in June 2020. Advanced preclinical COVID-19 and influenza vaccine programs to enable expected initiation of clinical trials in 2021.

•

Long-term Strategic Planning: Established TBIO 2025, a strategic plan focused on several areas of value creation and measured growth - adding key in-house capabilities, deepening pulmonary and delivery expertise, increasing research and development (R&D) investments as well as supporting infrastructure with a continued goal of advancing platform innovation and driving multiple programs into the clinic. This long-term plan incorporates an R&D strategy with a continued focus on mRNA therapeutics for pulmonary indications, an expanded effort in mRNA therapeutics for liver diseases and an exploration of new areas for application of the technology including therapeutic antibodies and protein degradation. It also includes the continued comprehensive effort to develop mRNA vaccines for infectious diseases with Sanofi Pasteur.

Anticipated 2021 Milestones

•

COVID-19 Vaccine (MRT5500): Initiate Phase 1/2 clinical trial in Q1 2021 (Sanofi Pasteur collaboration)

•

Flu Vaccine: Advance lead lipid nanoparticle (LNP)/mRNA formulations to clinical proof of technology trial anticipated to begin mid-year 2021 (Sanofi Pasteur collaboration)

•

CF Clinical Program (MRT5005):

•

Report interim results from 20 mg SAD dose group and 8, 12, 16 mg MAD dose groups of the ongoing Phase 1/2 clinical trial in early Q2 2021

•

Report interim results from 20 mg MAD dose group and daily dosing cohort

•

CF Discovery Program (Next-generation CF): Advance lead candidate into IND-enabling studies in 2H 2021

•

PCD: Advance lead candidate into IND-enabling studies in 2H 2021

•

Pulmonary Arterial Hypertension: Conduct preclinical studies to validate targets

•

Liver: Apply next-generation liver delivery LNPs to identify liver diseases for further evaluation

•

mRNA Platform: Identify next-generation LNPs to support liver, lung and additional disease program development, and explore new areas for application of mRNA technology including therapeutic antibodies and protein degradation

Upcoming Events

•

The Company plans to participate in the following virtual investor conference:

•

SVB Leerink Virtual 10th Annual Global Healthcare Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat on Friday, February 26, 2021 at 9:20 a.m. EST.

Fourth Quarter and Full Year 2020 Financial Results and Financial Guidance

Translate Bio ended the fourth quarter of 2020 with $654.0 million in cash, cash equivalents and investments and 75,029,625 shares of common stock outstanding. The Company expects that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements through 2023.

Translate Bio reported a net loss of $20.6 million and $31.0 million for the three months ended December 31, 2020 and 2019, respectively, and a net loss of $53.8 million and $113.3 million for the years ended December 31, 2020 and 2019, respectively.

Collaboration revenue was $51.4 million and $3.9 million for the three months ended December 31, 2020 and 2019, respectively, and $138.8 million and $7.8 million for the years ended December 31, 2020 and 2019, respectively. The increase in collaboration revenue, all of which is derived from the collaboration with Sanofi, related to increased activities for the vaccine program as well as a cumulative catch-up of revenue resulting from increases in the transaction price during the twelve months ended December 31, 2020.

Operating expenses for the three months ended December 31, 2020 were $72.0 million, compared to $35.6 million for the same period in 2019, and were comprised of the following:

•

Research and development expenses of $32.8 million during the fourth quarter of 2020, compared to $25.0 million for the same period in 2019. The increase is primarily due to continued development of the Company’s vaccine program associated with the Sanofi collaboration and discovery program as well as an increase in occupancy costs and personnel-related costs, partially offset by a decrease in expenses related to the Company’s MRT5005 program.

•

General and administrative expenses of $10.7 million during the fourth quarter of 2020, compared to $7.3 million for the same period in 2019. The increase is primarily due to increases in personnel-related costs and professional fees.

•

Change in the fair value of contingent consideration of $28.5 million during the fourth quarter of 2020, compared to $3.3 million for the same period in 2019, related to future potential milestone and earnout payment obligations. The operating expense recognized during the fourth quarter of 2020 was attributed to an increase in the fair value of the contingent consideration liability due to the time value of money due to passage of time and a decrease in the discount rate.

Operating expenses for the year ended December 31, 2020 were $194.1 million, compared to $123.6 million for the same period in 2019, and were comprised of the following:

•

Research and development expenses of $109.6 million during the year ended December 31, 2020, compared to $76.4 million for the same period in 2019. The increase is primarily due to continued development of the Company’s vaccine program associated with the Sanofi collaboration and discovery program as well as an increase in personnel-related costs, partially offset by a decrease in expenses related to the Company’s MRT5005 and MRT5201 programs.

•

General and administrative expenses of $35.9 million during the year ended December 31, 2020, compared to $28.6 million for the same period in 2019. The increase is due to an increase in personnel-related costs and professional fees.

•

Change in the fair value of contingent consideration of $48.6 million during the year ended December 31, 2020, compared to less than $0.1 million for the same period in 2019, related to future potential milestone and earnout payment obligations. The operating expense recognized during the year ended December 31, 2020 was attributed to an increase in the fair value of the contingent consideration liability due to the time value of money due to passage of time and a decrease in the discount rate.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: Translate Bio’s plans to report interim data from its Phase 1/2 clinical trial for MRT5005 in CF in the second quarter of 2021; the plans to commence clinical trials for a COVID-19 vaccine in the first quarter of 2021 and for a flu vaccine mid-year 2021; the advancement of lead candidates for next-generation CF and PCD programs in the second half of 2021; the goals and objectives of the TBIO 2025 long-term strategic plan; the potential for mRNA-based therapeutics to apply to the treatment of many diseases caused by protein or gene dysfunction; Translate Bio’s beliefs regarding the broad applicability of its technology; Translate Bio’s plans to advance its pipeline of mRNA therapeutics and validate targets for additional pulmonary diseases; Translate Bio’s plans to advance its additional disease programs; and the period in which Translate Bio expects that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forward,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to

differ materially from current expectations and beliefs, including but not limited to: the current and potential future impacts of the COVID-19 pandemic on Translate Bio’s business, financial condition, operations and liquidity; Translate Bio’s ability to advance the development of its platform and programs, including without limitation, under the timelines it projects, demonstrate the requisite safety and efficacy of its product candidates and replicate in clinical trials any positive findings from preclinical studies; the successful advancement of the collaboration agreement between Translate Bio and Sanofi; uncertainties relating to the discovery and development of vaccine candidates based on mRNA; the content and timing of decisions made by the U.S. Food and Drug Administration, other regulatory authorities and investigational review boards at clinical trial sites, including decisions as it relates to ongoing and planned clinical trials; Translate Bio’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the availability of significant cash required to fund operations; competitive factors; general economic and market conditions and other important risk factors set forth under the caption “Risk Factors” in Translate Bio’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 filed with the Securities and Exchange Commission on November 5, 2020 and in any other subsequent filings made by Translate Bio. Any forward-looking statements contained in this press release speak only as of the date hereof, and Translate Bio specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

TRANSLATE BIO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS)


	Three Months Ended December 31,						Years Ended December 31,
	2020			2019			2020			2019
Collaboration revenue	$	51,392		$	3,890		$	138,811		$	7,804
Operating expenses:
Research and development		32,845			25,025			109,629			76,369
General and administrative		10,699			7,348			35,922			28,632
Change in fair value of contingent consideration		28,490			3,256			48,575			13
Impairment of intangible asset		—			—			—			18,559

Total operating expenses		72,034			35,629			194,126			123,573

Loss from operations		(20,642	)		(31,739	)		(55,315	)		(115,769	)
Other income, net		81			703			1,528			1,990

Loss before benefit from income taxes		(20,561	)		(31,036	)		(53,787	)		(113,779	)
Benefit from income taxes		—			—			—			486

Net loss	$	(20,561	)	$	(31,036	)	$	(53,787	)	$	(113,293	)

TRANSLATE BIO, INC.

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)


	December 31,			December 31,
	2020			2019
Assets
Current assets:
Cash and cash equivalents	$	342,027		$	84,580
Investments		312,001			104,098
Collaboration receivables		26,598			4,596
Prepaid expenses and other current assets		11,741			9,391
Restricted cash		4,826			950

Total current assets		697,193			203,615
Property and equipment, net		15,372			12,539
Right-of-use assets, net		72,957			10,400
Goodwill		21,359			21,359
Intangible assets, net		79,127			85,536
Other assets		3,928			2,752

Total assets	$	889,936		$	336,201

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	8,839		$	15,968
Accrued expenses		13,202			7,072
Current portion of deferred revenue		67,563			18,100
Current portion of operating lease liability		11,733			530

Total current liabilities		101,337			41,670
Contingent consideration		152,230			103,655
Deferred revenue, net of current portion		228,659			25,256
Operating lease liability, net of current portion		50,953			12,084

Total liabilities		533,179			182,665

Stockholders’ equity:
Common stock		75			60
Additional paid-in capital		769,965			512,231
Accumulated deficit		(413,283	)		(359,496	)
Accumulated other comprehensive income		—			741

Total stockholders’ equity		356,757			153,536

Total liabilities and stockholders’ equity	$	889,936		$	336,201

###

Contacts for Translate Bio


Investors		Media
Teri Dahlman		Maura Gavaghan
tdahlman@translate.bio		mgavaghan@translate.bio
617-817-8655		617-233-1154

EX-101.SCH 3 tbio-20210225.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tbio-20210225_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 tbio-20210225_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g138712g57x97.gif GRAPHIC begin 644 g138712g57x97.gif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d138712d8k_htm.xml IDEA: XBRL DOCUMENT 0001693415 2021-02-25 2021-02-25 false 0001693415 8-K 2021-02-25 Translate Bio, Inc. DE 001-38550 61-1807780 29 Hartwell Avenue Lexington MA 02421 (617) 945-7361 false false false false Common Stock, $0.001 par value TBIO NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Feb. 25, 2021
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001693415
Document Type	8-K
Document Period End Date	Feb. 25, 2021
Entity Registrant Name	Translate Bio, Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-38550
Entity Tax Identification Number	61-1807780
Entity Address, Address Line One	29 Hartwell Avenue
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	(617)
Local Phone Number	945-7361
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value
Trading Symbol	TBIO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d138712d8k.htm d138712dex991.htm tbio-20210225.xsd tbio-20210225_lab.xml tbio-20210225_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d138712d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d138712d8k.htm" ] }, "labelLink": { "local": [ "tbio-20210225_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "tbio-20210225_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tbio-20210225.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tbio", "nsuri": "http://translate.bio/20210225", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d138712d8k.htm", "contextRef": "duration_2021-02-25_to_2021-02-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d138712d8k.htm", "contextRef": "duration_2021-02-25_to_2021-02-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://translate.bio//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-21-056938-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-056938-xbrl.zip M4$L#!!0 ( ,. 65+R'DA2CP\ -UG . 9#$S.#Z7^AQ&]K8@4P ;R@"146<)N4;,D JI6]\MJL >8KK&],^, ]]?? M<\8V&##A$9+L(RMUUV9>9\[[,>->_CX9.>2!"&!3BEI1!KN>ZP6@V9#P>Y_52.,Q6HH#C"M I M![V8X%8\;N)P]_/"L'%)#S(KE4I!M\9=5WK.%B@:1JF S3TJ6=Q=];@WZZX$ M=:5#%"X0C0I(>2RY]E3?+RT^0.1:NJPJXS-I>_0 M*0H,R]3()9]4<003T3.W;>:&S]"E%4H+<>D(QS)>O1XQUX;_U'N'#B(X)JK- M^M <"$V53\C?FKHGGY27>,O4^M21[+*P,/G*8MR^RORAX?@$*WYJN("4:1V6 M%-1INC:;_,FFF01(:SKL")H!TG9:*97-DU7X"DN8$:S/!.@])N$=!;\JM8S" M6D3KC"KJFZN,Y"/?0=[1OPT%@H)Z(1=K@/Q$VG$S%9;PD$1;JYAG4%ZUR\+B M?J+=+^Q8OTLO$.&KEJ%JA&Y-O2W0'0]CFGBS5V[C#WW.!-$@L%2%4&_^N4BP MY<$(=>K\/E#4LV>O(-Q"W8!>KLUABT?.V^:PVFOZQBVS96?K%!:P,\/F''N% MI 060%)K"_**HW+4X0.W:L%>F,@LMH^YK8;5\_P)=R\2?1W65Q%S ME=! >?$O@@^&T4\XG1]/AFHV-V2Z%6R[/YM">7XU\=KSE/)&^I>>)P#T^!?3 MGQ#I.=PFOQCZ3Z;VVR_FJ7%Q6?#7+53:O%!Q[X42TY9A$K*Z =('TN0D_Q^K MFN>S]SX=<6=:[?(1DZ3%QJ3MC:A[H=O&(=P]S[$O4LCS5ZO9;=R03O>ZV^BL M!\=X(7 ZC?I?[6:WV>B0Z]8-:?Q3_^.Z]:%!ZG9=ZTDP%@\!X]_7 MG3^:K0_=N]8QN@VR)S7H12 M6C1_7=W]EE(ZWTRL)-((%I+C!;CJ_5W[([F4/G5GBFC(%#U2+!^"V];R3A@&MMF 2\P2J!:T[&Q;NG&BAKSCWC%INE9^ W/LIAF, M0Z @VYA0T "X=90S,=LRH9)(GUD8 ]F$NX0K24!G@-B)98WVQM1KF/HIB,%D M#NTYC%C,<= 7TGE1(Z/??6K;\7NT5K17RW,YY$$0Z$S%V+#-(Q? M(]Q5C0C,JA''> B8"/^Q%T/'4OE7C/J5O=3ZP(3B%G4B[(8;3NT9S5/<89X8 MYO0ARQ/"7Q'L(N[BTP'+]02CGS$O"H%_E3YXP"%;(\[4I%ME=Z.Z @7C";"+6B]U%"B>NA>X2DSKGOTDPX?)5$QA*.8+ M[P&71E@UBGE_I_RPXW#O.")'\GCL,VGJ@FW;/"IJYTOG) MB;$68]\SXKITTHQR:I;&U)Y8/#5SYKEQ=G:^#1J?0]K/#R3L^]K]@\3<6:T? M,$+Q(# 0Y%^("Z3-=>BRDU-B/@-PX(?PI"X["FWKZXC%ZY*I[HU&7,JO@2JH M^4@HM#\P09KM3KB=QLAWO"D3KTZ71:T: M?R\G,:I2C!A.^RJLWBI#UXK*B= MT?=TKS*E5/?=T10Q;(3)#. M1RLD@K\PM?&$;/-!-,X\P??;+^=%\^Q" AX7Z!ZNH9^>_%W]M0\.UH],K)WY'7K <7N<3=[!EN5\DGNK'2Z7N:> M4C X" E;GB+4]QW@36"HI^13#^,?O@<5#_%42^=3!8E>(WD&9NJ3NJZ[V*2# M)H3<4JFB:L=;5O5Y2HZ;^"Q3JP^9]5E7R("5A 9X8Z0:-B(Q M-TNC+BEK\2!][J#>X!*4B&*N#517'I%\%#B*NLP+I#,E$H10]J=ZA6B UP-\ M:=DD4>4ND9 T#B.'0E. :+DF17E;-^KG*PO]S*U"1C,9@? MF,L$&)BF"TL$8?GR.E_,A[L_JJ[ER].]<]J'REF;\W-#52.1O5[-DB]ET;?S M$I8-?[A ^=>+5'.X3@W_+;@"\F,L'[A1G":?[#SV/,_I42"] D9%+%?.RN6+ M54V]R3=8#JK)(D7)D]7XTE&R3"W"!R @B1#B)ZKH[0"8I%P\B;A]J7B-->NL M>4;J[]ND6#+RT'$IW$UQ,-[8=D>V[8!&MP#A[N CJ$/0B*V=[1@40CG.Q-.%Y(.)I2 M!DR\B6!]0 M2-O/2.]*;%TP0%F_ Q*@^D3>$M9 M?BX)H!DB UQT0 ;"&ZLA!@<^9OZI)#;KXL!. M0B9T/2I3:ZPAPH83#_&P#WI4/1ST8A'Q<^((>+G_"'=BR3R5U?E*+6L(C*P% M%1C9]708%TBF>P&.HHH97J/A.K0+;\(C3O1:SA07'W-8&NGA GS0(M@#ES . MQ(.Z%N9IJ67A07CLC%_@L*FP95@KL]-CR%!CFJ4LG0622:;.DQG:#Q99?G<7 MY\.J;52[_?DG,#RI[,A&*]R(/R7H-[Y(SI5*+7"9/C!T]FKA0$U9ZH M_E+1?R[B#?F3A:Q907_'1,/Q>&G\L!]$@$674X/O[MHWC7:N?G=[>WW?:53C MAZ\[-6@:J;E!HA^!EU:37JN^05.Q4<@@Q;Q13/%CDI.]5B;O,5\_W&6;RH6\GZFD:Y:QA *T*/(I)VMV4]9U+XENJ M$?:CJZK').6*(G@>,@"U2$%#XA$T ?J9@DZFK@M*U-+G&6#S<^TJ(G2@5D9- M^270=P0U0OI< ND(7I8EH3:_81;#HT@A)"530V+DR35H=']VI&%Q:;#^_4"X M7 X1+G0PAKS'%:E4\B9J;>T?U ,A\&IP=',8K,76QS7RL:^QQWFF)U&F"UOE M[NP35$0RA6@$>P9>G=X5B@Q!:4F>0TON_YC((;@#VGKV&'B%8)3U*1-XP4-M M1>.BSQUFZV?S0E,)+)[O2:8Y>-'BG6_ISATC&>@H)&D6!T1K)3M'2QX=SZZ9 MC,$P$QGT_D777!..$8?3'G? 7PJ7I@JPH$$ZUARTL+OYK1!8%GR+V9>$\'R- MIYV V+D(\8GG:S&Y/K_H8D>WPHG&ROKC!9'3G-RHWL>R+W",&0CFA]=E-:P] M]%TT ^/AGAE% =SH.JVU #?@PQI&!W_RRQR8X*;SIY:DWNR.<5')&^8W:W?F MUJ43\W5H=B)]( ]C:W;28%G[*,3LZM\Q5(_P]+/?B3X,SV]1@$'',BK"1 ]V M2(CX;9MRR9I*3=A8*;UPN63K4D2DBTRT"3^U&#X^<9Z9:6X'Y\\#3^@LJB5IFS^BZW MR4ZQ9?T%LM-7O3^VJNM328;^UG-Q2IA;I23\L*-MEL[/S*+-)I6*F1^JD3XO M "YQ.W*);>T"K7Q\!G0M?=*EO^^!3*91?E8JU3WXE=S##B%@ DU"+7TIYX8J M2O0EV2Q&.#:ZQIB;TJX\=D7-1?#+LS,G]"@I53-KC8_SW(D6MA\Z@?*J=S,[ MS0^MZ^Y?[49GG^AP)U\J^16Q,$_Z)> B\O-VC\N.TY*M=@!!B44#3)#J #/\ MDE84,$K8.31XX<=^>@SBF3X&+CB1CI2B#A!(L0 C+CT=$&KH"=BD_5C\\NWZ M>JG>W=)9EO/8.=O*WWO$S8-X9Y>9MCEH8QY\QG+QX%.>+GBWJS[&2QB41XAS M0&_PV>=?N&G:;5^W.K?7W09YU[P[#F=JMNKY Y2/']O=4[XYL/MW!KZ&OJ_D M!,58QX\;5M?D>;]Q?JZ]FU:?CUUW.S2TH0"VH\4OR +XD8%#W@5BP YV1F]' MP7Q3K<\W__;]%_G@C0=^1!ZH#SF;%17= ;G3WWD0QR1LN&4#ZL0_ZLPOA ." M*5#X+\$QCX>HEP7]OPBYU/\#D=K_ 5!+ P04 " ##@%E2G#T0&H\? U M.0$ $0 &0Q,S@W,3)D97@Y.3$N:'1M[3UK4R+)LM^)X#]4.',VG(C&H4%> MZDQ<-15=O?L_58TA?29IIOMAP[GU]_,K.HGH" HH+VQNVH_JK.R\EV9 M60??VS\NOAY\/ST\^5HL'+3/VQ>G7T__76JU=O2#S_)/N/Y9/< .CJY._F9' MWXZO+JYNOFS]]?V\?;J%-UBQ ,\="]L7[M>#D_,_V6W[[XO3+UL/9M?O[S5W M:J:]Q;AEWME?MBS1\^FM@^OPL0%W[TR[Y#O#O?+0WV?J[X[C^\Y 7NHYME_R MS/^*/3W^N\<'IC7::YL#X;%+\G'^[_++EFG=]^-3!$4SJ^_G1 M>9OAS-C!YZ.O!Y^OOR8 2(Q>@=$S\(R!L_7U-[OC#?=Q%)CXM'E,> \1!6^< M__C&;F^.OVS=Z=5F0Z__;%UFPPYMVPEL UXZ^P"A:NA >7\3O%PK7KW+G"\R8MQ4O/\+DW? M9X?=KNF;C@W FGC#'+ N]SD3OX;"\$47KC*8F#5BOU=8SW4&[+K//<'TSQ5F M6*9M&O"F[^)DG1[[<=.NE-8J%G=ES',SVV M?7SVB2DX5C/[]H,#$^S!3$TG\%C7] 1.;G!S>$/39U64[8OJ^Z8N2-^2&V+.=!Y7_UY?E+26P>?\+P(WB?,I;/N22#_U?-ZQ3*\/J&P?G5\A\FK,8/;QI\*$/E^3# MSG#HN'Y@ \$+KU@ E V .\VA)9!8 :\B )E'(C6>R6Z1$%S#)]/"ZSM2^YU^3][A.)/ M&N/%0LBO)< B(!,@\81]!^2!R-E&%'U*(L(#BAH,N3UB7<"_Y0Q-^XYQ9@/P MA@6 (D\/'1\6%[@?!(2/W\?% *\Q^&[)C*0A^M @H"!5!BZ,!;(@Z[HF);I MPZ,P*%RWS)XH^7U\3-AX3?&BI\'K73Z"!98"N,MZD7AU$^*U$WCX,8_U8SFK MQ!"('"FS_TG([![*[!'*;&%W15>B]00$\Z #3U1UPF]YY\4) !9OM[%/>B, MNG:ER)5HAJ5 )$M*=SS/))P!\4KBQ.DI*44X*!:2JR>?@;% ?AA]$L<@R@: MUFC,>(DZPN # 9^%!8!/C#0$J[G//&YV 5)0#_!#V#SH:LSHFZ('TE 8 2VT MT^N9!N ,1DV1(!$RS.TO@2P%W.>;\'7B,,"_*P8<@.LY1N#!G$%BP1HQ>,!# MZ05C)8@N ^P$>BH60GJAP1\$R!/G)Q+ W=)8GLD0RRX#1"80XZ"'%8$)(J# M8RH9KL$OAA5T\:N(,5O\\B/%R $-(U1,!P 3]&A1K#2PH"@LVGE87FE_ 8,^*"=HB]$:J@SHD\KT:X5"VGAO@>+ M.+<:"G6= 0"975P_!7#/=#T_Q3<@D6-5-?&]F977CB2R$(B75D=?)0 ,2 ML ,!I*P(%)>* \&)H20US\ U-(&L8<# [M**P&JA:@(U!=/U^LB09#D15N0? M*/4<-'<"(!8#C!Q/+I4Y%+",0D.Z[,"O0(KX*W!%L? @+*L4CB6-BU!I$<6 MKX" -G&PC9DX!T&O-7G]VG%&.E4!7%*F?:!;<1@"#8<(,V+N8)TGA0HL+;, M0/Z*S @NV129E'?O4?@B4X:ZT[3OX?/F'5=V)$JNKAN KA@.+8 <+X.Q=WYY MXH$>@KO%0HB1F*H)B:$R-T'6WRLV /AB3NPABE%H@Y9L]X$3:5(/)HCR#N 3 M%AP(%"9H]Q60WE#@.O$S9-)=D;9"F M00"E$$.#=3R2#H#DEN/>H7U.9U"AN[TX='%:3C4T=7-R>E-"3SGB\/KV].] M$='XG%Q?7AR0F84-'?M]>'Q^'??YV?M+]_V=++Y7]M M27AN@"E&0+=?V-80[*!2!VC]9\FT/;,K]OB]8W;5@R?AR[O_BB?5/AF_R?Y4 MEBX@);)ZI7^/"]N:])J>>6W"!Y(#I9_%Q4G=5>AEZ<5ATREF1DPCQ62=NG;2 MJ3L^TQ(>X7&HK=JH#_>(F(Z1O 2JVRY(.>!)T6LY, M[YJ9KM!$9]>!-0!=":KB6BE R2N'I%V!H%';E>X$&'A2#8(A21H2F /?,D"5 MX<_NR/N)^L/D;/OZ&,@QTJ>HMT'/AF8)F,F1)4G,I<:6K.0%Y!E/,4.?M.= MLY? M +[P[X+C3G/!R-:VM4)P[?/K1X.*7ET*K-\/CG_$_Y6@=1B@=&_!T-) M:VF]* 9CZX*7$L38$:BJ][CUP$<>!A,/OM^PV_/_@]E4M\(A*9:[]Z%%_Z0) M/22.X]/+]NG- H'>M\&_MJ&CAG\H)2K/R*?G'R%_@Q8'> M NN/[&!E+$X(UJ7]. T^AJQP]!65Y',"BS_(G(WL/1R&6]:D>&<41("W_C> MJ,Y G.1](A^Y/K V!;,03'PX\F^SSNGV MS6]\,-P'XT$Z\M(-A+EA9 )_*NM FNX]%\23&Q@4H)!&!H\C*NS.D=&).$PP MR:DG$%SS/A5&B"0". &.E)'$^,K3C_<':$5@9HX[1/E)(3^F)A$NW"@,7,2@ M12$,-D9#:N7RISW:>CN7EHJ8 MOBMNVL7"[[JDR>W,/FS*"/R4VS,YT3Y*M&=6$-*AI#YEH#-+\"XHGZ'99390 M&&X-F08@=OOB\OK39Y+EJ((#2\7B_?2^DD,^>4+M$.6"8D_(5 JXW>GV2AO3J"Q!193.(Z(;V M"J*]_#!UA+;R*7K/;@]/9&1?QO31M*8= 4UN![ ?J?M1) ?\$@3*3^^,T/JZQ.[1)7ON6S,:?9IFKT^/GF2&A?>LE3$B/LO.37FU/@(-491 MXT/,D$1K[_L(P^^"MOLDI1X[=C7UT1I@$Y,:QUE-RHPOM_##'FX*' _BT;) MI5].AX_3(446K]4&GPJ(AR26)A(+_M]K(O&W[]93@=M7\$MOV]@N==Q@KAF*R#3J)"C M6,@0,<YCUMC/88:>W[16E M),Q1*%XL)"O%X_KQ;P%,%)W\_DCLR81!3];IF#Z6!V!]H2K0F@$ *AQ2 MV8XH M[;*Z$Y:TO=%\YA=K7)&AQ:C, ZMBP7)T9.WQQTIYIYZF/5RBCU4]2Y)1.X*^ M*[!$S_;[GJ3P8B$L^95OA'6_-%*EK+[[9:E)" M?-2KS8D8;F2O+@&_*%]4UJ08;ZJ@T*%1(C6L?528U 75>(])AKA)\VA^-W[0 M"E,JPB\!32$$E.$95ZUGT#./GQ ?P&0! MPJID)(@F6R&X4C7JG6LG*OP1K3K;:4G0,DK52FZ8J)Q!R5CAZJAR- M-IYE=72<8)PN?Z8AE=F&BU/?][*5("#5/,:^IF 6^*!GN^,J#= /%ZT M" E!/F%^8=FL C O5\E9_A&6_T:14DN%0@>F;5(E V7G)YE>+^\T%F3ZQC2S M]'D\GS(9IK!5&%KM"6KO O/L">'E+)&SQ",L<=SG]ET>HQ1BH4Q3D''9G9&29GUO8 " W&_EJC1D-R] MX*[M!#ZHFI'4CQU+=4_Q)+^-!1]@<,.YLP$WW:?YG9PU[ONNV0D40!F-&.(3 M70R%T+@\: )2+9.KYBF*Y\FHAO6+%P2,:Q'='H(NQPYC."X^)9WFI Z-^J4$ M\#&LV)JE=<)KN@QQ9[#'706]M;NC/^8KZ)7JO,X"#5TLY,Y"+B:7YBSHY5:6 M#!."Y$EJCXFZ6$"J;M2SH:"WYSB\II. H.'O@*ZH$#9OD)'+H@V31;-Z,=5: M-F:\B# "4V]V#3LNC)0(RMA(N2>3L\6*/1GV<7>,LB?RR;1=K+0I:F%W7!] M81_+&9MU[3R;&;)5$#WC"O$?N; MX&"T?JNZV4Q.L .XI0J#5/E78MPS &978"%A#-VG(Y:CL>IHM',"#[>0W(@QB9H MDNC _6K5RUDVO(%O%@O8+Q;34J6$N@<:0%HB6I:V4+0B\%DO0#?.FY:?2NVN M)_1Z&>M,$ E4E+ A1EV6(9Y$WD= M&K24>JM5VV&W2#F9;Q4+B8^I/D : VU)7&H[F(,],*7N1-)U2!LKG.ZEJ2KT M5Z-,4S==I$H])64& 7QL:C,4I+30Y36IJ^7$QNAAB\C]J#FZ[%GA# :84#C6 M$8Z2OU4:1+'PC+[G$[N=*R#BYGFL9P71*\_J@R$G))MCB9 9TP5L M'Y\D^V2E>NVO*[V S+NFP.)W_2!T55:T_??"&0GYDZ2%8*#=*'4I822EM M%*8D74.S*=DB>$#J?"XUO#^9^DBZ][R82F6>#(GT,/M?V7#PW;0*F#)D1%QJ M4>BMJ#UY5$60G"PB=*QFBPCD,=4XS_>GUT+ ,.K, (I.*3.=TI"D?9S^"%U: MPS1)Z0P\.&[74SWXXUXSX=$3\KI2Z.IBL2"OAN'"]+-@:%O=]"5L3#\8&U1B M)'U-"<_T111O=N8:J/7T!5S"S)60:3*7731/_>Q%YS]CP'C]Q%3"24M22S_X M@,^I*XAX#R2ZA:[3+])'U.T'I;V M3TE4>/J+BQ\BA4C4C&8="13,G\,\="%K91PW:IN UD:D9&1\ 0B! MH\A2RFKN;FW4L'$ B@RK&">K$G5E@FR"^Y-TR*A MUDG(\0E6-ZF6Y(%5H5!/X@NM0O36"5_JX!%IB(?Q"$NVZL5Z8A(=U!,4M(U4 MWU(WD+#U %',XSVA3KT06&?!C4@YPOM4EYRP/>3)/+*,3N:_9DPM*C<*NXKW M3,K*5[U))I0W2QL"W!H#4-T+K*SI,YXIR^]<(6]WA/\@A)WU\@! Z7SLIP4" MSMF2JD@9(8^=QS%^<@V0!%B-.EIT_P )3#1 BCI@2!E[&G<84]#1LF1_YJ!!LG&I&Q.Q*#8:,B==0*=7K/+._3Y.UT$.$: MP\.;2.@38=E T@:68^(ZH]6#BESA34X:%9!E"2FET;F'E1M%P1-'69O\GH/Z MBDVXY.DW9*8H(Z(;&B'%0LRI^Q0[$KZB3:E ]E6L!E0#+*8S4*=/@6C\*?R8 MX[TDJ*$6(MT3#L1PFP_;I/83[(@G]2#52F5\@X^?R<>53C;MR1A514$@4%6W M'ZQJ K$P0Q\5O5SZ/91S8=BV!Z0.4PP]%ZGJ;\703T9.RRIRVC.MU%9I[&0B M#DY_&3):?0S>5G@:EPT>]WUBK%HBBYYH8*1P!UK=@R6B )-ID6P(>21S-MBA M/<)SV9XR*N3A'OZXA^T-00L#9(!"'BD*,LGQ$#6G)S,ITL(#$_V)G%"3H7BP MN#F0,BV.5"-I!4,:"6],!1&/)1$T:*;7(-@&BQ?<> MP+1_ER5"E=T7.K'UYO#R]N*P?7QSE/QGV7821,@.;ZZO+VZ.#\! M6$[@J_#C!V#REEV=L:OKTYO#]CD\L"+8ML\O6?O[U1^WAY9 MW4+,;C&FR"VQ%;G?/P[ZSX8;6^IC6*UHE.VB=G,*]I$4INR-./[OG,_P8#$@&#A M0CU+-^$4P$H%S1^2OKY3QNUAS[%@%A_*](^40UAN)+_W@VJ.Y.^GX^>,1GN: MD@L7@/XUYX<%S,N=TT:32V5!=*(E]:KKOSC Z&EO%,!O&\/$/K%N8T??R+;[ MLO4!'&_P^K>6QE0RGR4#491-,T\"C;J$EB+A 2U8'W<]3!L#B'NE\.+BU1P\O=QAU3RLE[5Z:T.(3:ON-C<"TFI-:U5>V99_KF!L:O7JG*#F M6ID\R*A68[8ZC55S.JST[FN[;L_E'ZU2JV\$I+M-K=;8$+NBFNOIIWCZ?# $ M7H[2<&P?6-S$;$;,PE^YO?W;![VF[\N7%_A6#O9;!EL'B51;W"1/L,WPUSZ; MND&R6'!@7JY747%*;L"0^*]L2#S>8%[]9Y>Q4Y!C*,=0CJ%9,;3)CDEM:49, MV\&*BO&"BU6;+XV*5J[.N=&Q.@=^4T)P>FM7TRN;X2WIE2JX2XO[(;EQDBN6 M'$,K_VR.H><:)^MMBBQOS_X"CSZ@FI^X^F+59LAVI:S5=V<)>7]:O<;DUKS+1Y^6D*%V^:B['$7!Q5JF4X Z'A(2>K M9NKF*Z=Y/=<%*L]I_*[*4-=JEQ2-;!#@8/HUR=)7ZX#L#6JEJCV=@0 M8'4=H&WD'L9S&/UH79E[0],"8?7P:CR.9\"Y$F?C&7"NQ,]X!ISH8E1:LP25I[D8FV)M5*5 ZCH!YF._ MGB"'%X>G[+; M[Z>G[;PWWEKUQFM69FU?5UEFQ[FY!GL)%V49+<2>?.Z1KE%(DJMM%;=TD-[B M,N7=R,:7..]&IHY>PPI3+U0D2Z##3>_W\U[6_C@\WX (8,:>5F]^]3=-%BRQ MKP2VKY=GXZ2/VWDN92RO4UUUMZ*5*[.$Q58:%6/-7:W67#PK\,V3VGE\=M.2 MB>N9^Z95'0BLO!FYO'IY5RNWYLR2S47YXZ96MU+7:O N[ M(B($0==:/-7@S1/:&E)*W:NM4]9%G@.0Y,F\P1V;9/4G64=?66PU- MGRF#8O5"KU*N:O69"FS?B+I=7I3M.CQ)D(XA_"^7@X+-C-]IN>0$#\OW*T6^.T\5CWM>#Y"JZ5IVWV>6J=/_OCF: V:Z"C%X@,OE\)=Z6.ZET?%Z6JM3:D&T=%:]06.$P@C\OD M<9D\+O/Z<9D7$7;/V;=OMK36O%IK45'WG#R(:EVKS+M-O;F";M/* 58AZC8- M1[FMI_(N+TS>,2W3-]6N\*WO&#_[C@4(]G[[H._6]]GI/X'IC_+4S W1CLM/ MS;1B&LGS,S=39BQOX_[0,)S ]CTVY"-,6EH#LTEKSAN.7X'1I->T5GV!=+EW M1%]N(+IS'MOPXA'S*EB\F[$]U=#*\VZDY9(MJ>Z&CDN)F4Z/=45/P,4N<\6] ML(-E"[OG[MDWM%I],[;L]::F+[+3](YI+S[!QA+<$Y$5-EH/(L0DS>IF$&&M MFB?+K67(,0_*ON4XQ4NESR7KD)<8^W 6.<;Z MY;/E*EIE7JVV*A,0LS9K>=;F,XCP).-^4"X(';*>-A?7@R@KE28L](:D(]7F M/V/]/8K!JVE.R'J38JVLM6J;X9Q@R6]SSF-!<_\D]T_6 T.;K*>7[9^LG5]2 MJU8U?:8#&-9 ##8K6KV^@)68R\%<#JZ''%QOJ;<\VW!"JHB@5)$\26 S%>(R M.YP,!H[-/*20]="%C3E5RXK48/W-AN:6F"'0[9KH:H+)]60%(;8]@:^IJD%F M\*$)IMJ:D&2]I;7F-7E6M86F8\ Q[W3RO(268!!8'%N==$7/-,PU*>?:WL6L MEN:\IR>LB *WJ[66MCM3MZR_4>7+K080;>L+9 MW/VIDC% M]R4#K4P%V&O)Q+Q ]JW(PDTK_ER%--PT'!UDSA2;>+H4'>TT"8!YQ%#VX)P/ M'SXP=:)5?HK9_ 6]F+C(#=^#!UW6=KGM82" '9G.X\=TU=_-*5W5QJRG=.GI M@[7"R_7HP*V#S!$^+V\YP K+8PLP;O^=W?37SK6]4:IB?]13G"RI^/BI+P4X"K5:DG7:[L3@,LJQ/B MZ_\#4$L#!!0 ( ,. 65(!8 5K9 , !T, 1 =&)I;RTR,#(Q,#(R M-2YX\@@,ZU4EQ*OH +H:AB@DKX MWC'^ RX52^!,2IAXF$6:EIL[7B2MU0=;Y);=\I*^?@6 \5(V5VBR+L>1#T0; MAX>ID8DV]H%%TOEP,IRELSU'4'!=OM>2VSW9I"F M1P0KPV' >0\BA?IG#\*+IU@D_4,V(/=' 9"-1B,2I&N4"O?8C];ZD#3"GK85 M;+O+*/ N9SV7J7-&3&O'+[0IS_F,UA+/J=6OFDHQ$[P(6ECC)5?NDDW$@+R;2U<*SB"P+Z6 B=E?9^T6\JO]='/:U MS+.CL3X4?"Q&/A;9AX-BL3%4_@,F6EV_E$QO,CZ%T-86]8MXU:L'I6>MO9]? M(XH*%H;O<;/T1(Z?0&2%?VFE] :==F$SR!,XIP:9K3D^^Z/B? MW:T,?ZJ["+%X[82T[?;Z6T_KR<[[H"+6;I?Z'C]7. M0G])50&-.>C9.R'K1M;MUY877]5I6#,J62V7$6_!K<8^X'JN#D>NF.W&M;M= MMKH>)NM-W.[TF[W9:H8-?OX+4$L#!!0 ( ,. 65(-M0#-8@8 $A$ 5 M =&)I;RTR,#(Q,#(R-5]L86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"RHV3= M$*-ID3E)82QI@L;=A@U#(4N,38PF#5).[&\_4G\:.:9D*CI->=%6D>Z>NT?^ MG4K+&!]PO\NJ(L&IH??-\_Z/O%-$D"HP=1$),A' X.?Q[H M0!_\X4]OAV_?PND5G 4^B?J;**/]W:/Z:FN;A]2L ?1:Y2O:= M],RYR$[%>BI97\B9[O7@:)"G]!XSUCLI#T=)@G]\?#Q(CA:C%;7%:G%_\.?5 MY6TX)XO TV=?OUIA5D;1H4KV7XHP.84.#4)IA/G)R\,\L\OS#[TCO[]64>^] M*9B=G6!*V*7>@L3#4 I&*@J;PTGU7A8?;Y8ZGJQCPB.2*7_3%F$6-9?D+E4U M["62BH3]F;@?1(1J:?_8;'AFPSOPLSZ_U[N^CH2&_G2J8AF$\7959DZ4D/G. MQ,I)SY(TV&[+Q)W*<$LKD&&NHS?WG(4L8A *_>HM8R]1S-/OI%A8N\C*"H+B2*7=?O% /-TH9'7?^(+%LQ?T;V;C"69+<$:355D1%4!-H*P21X$TK M0%8"DAJ@BS3&N,76BSC7[Q\#[#,1KLP,3;0'5YZWG>(]4I M[&XVA7-*\U%PD,>=C*V"D%2$K"28FDBC\C_XLDS.\\WAC=(%9>33:C$ELM[< M%/,Z'1*+ 6$_WAS_IUJXK!MU2.61L,;NU\*P4]-XN$Z"]3C2BRAZ1]-;ZL]A MMU2D4Y#W61,.PQ: -@U6UI"M+W?AJ@O!KN*+1BI6H>:OA!'XH; MH>* _467]6\&V15>PD#83=G&82L2;1@LJBV-0EH)="G,&SSMV:@: V!KML]!M2W@M&0 MQI3/KO1Z7-* N1)MR^P(YPH3HBRB"&\D M,;-"-!S)(V;FZPCR^N[.?2E1I= 1S ZFQ+[()G#O4T6"7)>!8AU("T%2J3'N M;9LH8O],)RT,P%BI%9'-Q\"B\S*&H=R@?21VXA$'HT2[K?%(R[4Z)2TYJIR5 M6K90%CPD7.EUUL8_G$YHS)SO@^SF=;78*3,@[,<;+72L6EC+G$P5@$T0M0DA\9LJ02C=F MLX5&BV"Z=HMY#3U?AW/MF=1Y8MR>V_&UU&I$E,=@7%-W];"OJWD%G"?&V^O; M>GUU;![OL\'S!9$S/4$?I7B(YWJ1L@QXS6]1EDAT^NE@M2VQ-[3YYX,5LDC$ M9Q^JY84@K019*:3/!UNT8?F T-5+<<>EWC*_ 2/;1=/? Z'W_ =02P,$% M @ PX!94J]3\>.Y! "L !4 !T8FEO+3(P,C$P,C(U7W!R92YX;6S5 MFEV/XC84AN]7VO_@9F]:J2&$&78[:)@59696J/,E8-NJ-RN3',"J8R/;#/#O M>QSPBD"8A6FWBKF X/@]?GT>QTF<7'Y<9IP\@]),BG80U^H! 9'(E(E).YCK MD.J$L8!H0T5*N130#E:@@X]7;]]<_A"&Y/JV]T!",C5FIEM1M%@L:NF8"2WY MW&!(74MD%I$P=/6[P\_D]W5S+=('#E0#:=0;]? #^77.>-JR?^(XKM?B;9D" M:N.1E!IHD4;4>!]AQ9C$K?-FJ]DDG7MR0[4!) MO'U#\(-Y%#HO;0*UZ2:H-OZ6>1$P;9FN2=:G.62^.+B(LKW%NMK M5E8;&XBC/^_O!LD4,AHB V26[#2%;E+S5;UMKAFM=[KZFK5T'NE.)GGJC^@6 M.5C#_@M=M= 6A7$C/(MK2YT&5[;)=5:5Y-"',;&_G_N]KVT:187FR+XV8C+* MT=<;C69DZ%(*F:TB*XBN93+/0!CWVQ'IC3#,K'IB+%66=R,@>49;4P7C=F P M7.BB63/O^ACHRRF!S&J&!X5FV8Q#0**MSLP4#AQA\MIW6% 0P-* 2"%U86P' MOD=WK]8\-X-6)H7NN\,VAZ4AJ4WD<3HZUM2,JVMKFUU%)(215 MB0N'FP5X^Z-_4R.:487QPF2*\YQ3CY7,2E.T:4V6&I4J!=4.&HT:'O4!F2DF M%8+'DH#,-7J1,^N:P_&_ M_ U6Q\(Z(*XNM .&';PSS^"Y>6:(R3R665%3751%GXY0TU-"3X".\6207N,Y MY%14.^+J,]LQ[."]]PS>>K;HPX39[@KS0+.CV95KJXNNW*\C]\%+$EK2)>]%)/!QFQ]&_L:= >#5)WC0>,;J&=U+Z%VTA13K3<_>&L-\6E M2P-4'6:I:055].D(^;988Q^L\*>I%"?>3NSKJDMJWZNCY=OJS!_HTH#HRBR;B\W5 MM#X6V0%Q=;D=,.S@^;9 ,Y"<)Q^/C)\J7(E27X4NN'4O?UF)V^M33>@[JWQ,MB>,-UQ+O M&[KGOBW*#""96Z-Q8S1DAA]]N;FOJRZ]?:^.EF\K+T-%[=M=@U4VDD>?!G=$ MU>6T8]1!\FUMQ0VWFV4RI6("ISP++-=6%UFY7T?.SS64FPS4!,?A)R479HKS M_HR*$]]S.1"BNAQ?M.UP_@_+*)?17FKNL,"^N;G>8[_L>XA8\@]02P$"% ,4 M " ##@%E2\AY(4H\/ #=9P #@ @ $ 9#$S.##DY,2YH=&U02P$"% ,4 " ##@%E2 6 % M:V0# =# $0 @ %Y+P =&)I;RTR,#(Q,#(R-2YX&UL4$L! A0#% @ PX!94J]3\>.Y! M "L !4 ( !H3D '1B:6\M,C R,3 R,C5?<')E+GAM;%!+ 4!08 !0 % $ ! "-/@ ! end